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Prevention of ventricular fibrillation by 
dextrorotatory sotalol in a conscious canine 
model of sudden coronary death 
The antiarrhythmic and antifibrillatory actions of the dextrorotatory isomer of sotalol, 
administered in a multiple-dose regimen, were evaluated in conscious dogs 3 to 5 days after 
anterior myocardial infarction. The Intravenous administration of d-sotalol, four 8 mg/kg doses 
over a P4-hour treatment period, suppressed the induction of ventricular tachycardia by 
programmed electrical stimulation in six of nine dogs tested, slowed the rate of the induced 
tachyarrhythmia in two of the remaining three dogs, and provided significant protection (5 of 8 
d-sotalol vs 0 of 8 vehicle control) against the development of ventricular fibrillation in response 
to ischemia at a site distant to a previous myocardial infarction. Increases in ventricular 
myocardial refractoriness and in QT. and paced QT intervals suggest that class Ill 
electrophysiologic actions contribute to the antiarrhythmic properties of dextrorotatory sotalol in 
this animal model. The degree of beta-adrenergic receptor blockade produced by d-sotalol in this 
dose regimen was negligible. These findings suggest the potential utility of d-sotalol in the 
prevention of ventricular tachycardia and ventricular fibrillation in the setting of myocardial 
infarction, particularly when beta-adrenergic receptor blockade Is undesirable or contraindlcated. 
(AM HEART J 109949, 1985.) 
Joseph J. Lynch, Ph.D., Lawrence A. Coskey, B.S., Daniel G. Montgomery, B.S., and 
Benedict R. Lucchesi, Ph.D., M.D. Ann Arbor, Mich. 
Recently, considerable attention has focused on the 
use of class III antiarrhythmic agents such as amio- 
darone1e3 and bretylium4m6 for the management of 
patients with malignant ventricular tachycardia 
(VT) or ventricular fibrillation. The characteristic 
electrophysiologic property of this relatively novel 
class of antiarrhythmic agents is a selective prolon- 
gation of cardiac action potential duration, resulting 
in an increase in myocardial refractoriness.7 An 
increase in myocardial refractoriness presumably 
underlies the antiarrhythmic and antifibrillatory 
actions of the class III agents through a suppression 
or termination of reentrant circuits by interposing 
refractory tissue to an advancing wave of depolariza- 
tion.* 
Racemic sotalol (d,l-4-(2-isopropylamino-l-hy- 
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droxyethyl)-methanesulfonanalide, MJ1999), which 
initially was introduced as a beta-adrenergic recep- 
tor antagonist lacking intrinsic sympathomimetic 
and membrane-stabilizing activities,g, lo has been 
shown to prolong the cardiac action potential dura- 
tion and increase myocardial refractoriness in 
vitro11~12 and in viv~.‘~-‘~ A prolongation in ventricu- 
lar refractoriness has been proposed to underlie the 
antiarrhythmic and antifibrillatory actions of d,l- 
sotalol in experimental postinfarction canine mod- 
e1s18s lg and clinically in patients with recurrent life- 
threatening VT.20 Recently, this laboratory has dem- 
onstrated that both the resolved levorotatory (1) 
isomer of sotalol (the “active” beta-blocking form of 
sotalol; the optical activity ratio l/d for beta block- 
ade having been reported to be 44*l) and the dextro- 
rotatory (d) isomer (which would be relatively 
devoid of beta-blocking activity) acutely suppress 
the induction of VT by programmed ventricular 
stimulation and equieffectively increase ventricular 
refractoriness in conscious postinfarction dogs.22 
Administered as acute pretreatments, however, nei- 
ther optical isomer provided statistically significant 
protection, as assessed by 24-hour survival, in a 
conscious canine model of sudden death in which 
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Fig. 1. Conscious canine model of sudden coronary 
death. On the day of surgical preparation, anterior myo- 
cardial ischemic injury (broken lines) is produced by 
Z-hour occlusion of the left anterior descending coronary 
artery, followed by reperfusion through a critical stenosis. 
An epicardial bipolar electrode (A) is sewn onto the left 
atria1 appendage for atria1 pacing, and a plunge bipolar 
electrode (B) is inserted into the interventricular septum, 
adjacent to the site of occlusion, for the determination of 
ventricular excitation threshold and effective refractory 
period, as well as for the delivery of programmed ventric- 
ular extrastimuli. Plunge bipolar electrodes are inserted 
into normal, noninjured myocardium (C) and into poten- 
tially infarcted myocardium (0) for recording of local 
activation and determination of ventricular activation 
times. The bared tip of an insulated silver wire (E) is 
inserted into the lumen of the left circumflex coronary 
artery, and the wire is sutured onto the surface of the 
heart. Dogs are returned to the laboratory for electrophys- 
iologic monitoring in the conscious, unsedated state, 3 to 5 
days after surgical preparation. 
ventricular fibrillation occurred suddenly and reli- 
ably in response to ischemia at a site distant from an 
area of previous myocardial infarction.22 
The purpose of the present investigation, there- 
fore, was to assess the antifibrillatory actions of 
dextrorotatory sotalol, the “non beta-blocking” 
sotalol isomer, administered in a multiple-dose pre- 
treatment regimen, in the aforementioned conscious 
postinfarction dog model of sudden coronary death. 
The essential experimental features of this canine 
sudden death model are illustrated in Fig. 1. The 
beta-adrenergic receptor-blocking actions of d-sota- 
101 in this protocol, as well as the effects of the 
d-isomer upon the initiation of ventricular tachyar- 
rhythmias by programmed stimulation, were also 
determined. The results of this investigation demon- 
strate that in a multiple-dose pretreatment regimen, 
dextrorotatory sotalol suppresses the induction of 
VT and provides significant protection against the 
development of ventricular fibrillation in response 
to acute ischemia in conscious postinfarction dogs. 
These findings suggest that the dextrorotatory iso- 
mer of sotalol may be useful in the prevention of 
lethal ventricular arrhythmias in the setting of 
myocardial ischemic injury. 
METHODS 
Surgical preparation. Male mongrel dogs (14.0 to 18.0 
kg) were anesthetized with intravenous sodium pentobar- 
bital, 30 mg/kg. The dogs were ventilated with room air by 
means of a cuffed endotracheal tube and a Harvard 
respirator. Using aseptic technique, the left external jugu- 
lar vein and left common carotid artery were isolated and 
cannulae were inserted. A left thoracotomy was performed 
between the fourth and fifth ribs. The pericardium was 
opened and the heart was suspended in a pericardial 
cradle. The left anterior descending coronary artery was 
isolated at the tip of the left atrial appendage, and the left 
circumflex coronary artery was isolated approximately 1 
cm from its origin. A 19- or 20-gauge hypodermic needle 
was placed parallel to the left anterior descending coro- 
nary artery and a suture was passed around both the 
vessel and the needle. The suture was tied securely and 
the needle was withdrawn, producing a critical stenosis. 
The artery was then occluded by means of a snare formed 
from a loop of silicone rubber tubing (Retracto-Tape) 
passed through a polyethylene tube. Blood flow through 
the left anterior descending coronary artery was restored 
after 2 hours. 
An epicardial bipolar electrode (1 mm diameter silver 
electrodes embedded 3 mm apart in acrylic) was sutured 
to the left atrial appendage for atria1 pacing. A bipolar 
plunge electrode (25gauge, insulated, stainless steel wire, 
5 mm in length, 2 mm apart) was sutured into the 
interventricular septum adjacent to the right ventricular 
outflow tract for the determination of ventricular excita- 
tion threshold and ventricular effective refractory period 
and for the introduction of ventricular extrastimuli during 
programmed stimulation. Two short (2 to 3 mm) stainless 
steel bipolar plunge electrodes were used for measurement 
of ventricular activation times. One short bipolar elec- 
trode was implanted in the distribution of the left anterior 
descending coronary artery distal to the site of occlusion 
(IZ = infarct zone), while a second was implanted in the 
left circumflex coronary artery distribution (NZ = normal 
zone). A 3 mm section of bared, insulated, 30-gauge silver 
wire was inserted through the wall of the vessel into the 
lumen of the left circumflex coronary artery and was 
sutured in place on the surface of the heart. Silver disc 
electrodes were implanted subcutaneously for ECG moni- 
toring. The surgical incision was closed and the animals 
were allowed to recover from surgical anesthesia. 
Programmed electrical stimulation In the conscious 
dog. Programmed electrical stimulation was performed 
between days 3 and 5 after anterior myocardial infarction. 
Animals were studied while conscious, unsedated, and 
resting comfortably in a sling. ECG intervals and electro- 
physiologic parameters were determined immediately 
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before programmed electrical stimulation testing was ini- 
tiated. ECG intervals were measured during sinus rhythm. 
A corrected QT interval (QT, = QT in msec/(R-R in 
set)“?) was determined during sinus rhythm, while a 
paced QT interval was determined during atria1 pacing 
(2.5 Hz). Ventricular excitation thresholds, effective 
refractory periods, and activation times were determined 
during atria1 pacing (2.5 Hz). The ventricular excitation 
threshold was defined as the minimum voltage required to 
produce a conducted ventricular complex at a stimulus 
duration of 4 msec delivered 300 msec after the R wave of 
the lead II ECG. The ventricular effective refractory 
period was the longest R-to-stimulus interval at which a 
2x threshold stimulus (4 msec duration) failed to produce 
a conducted ventricular impulse. Ventricular activation 
time, the interval between the Q wave of the lead II ECG 
and the largest deflection of the local ventricular electro- 
gram (Q-EG), was measured on a Tektronix model 5111 
oscilloscope. 
During the programmed electrical stimulation protocol, 
premature ventricular stimuli (4 msec duration, 2~ 
threshold) were introduced into the interventricular sep- 
tum by means of a Grass model S-88 stimulator and a 
Grass model SIU-5 stimulus isolation unit. Single (S,), 
double (S,S,), and then triple (S.&S,) premature ventric- 
ular stimuli were introduced. Single ventricular extrasti- 
muli were introduced during atrial pacing at S,-S, cou- 
pling intervals decreasing from 350 msec until ventricular 
refractoriness occurred. Thereafter, double and triple 
ventricular extrastimuli were introduced during sinus 
rhythm at S,-S, and S&-S, coupling intervals of 182,167, 
154,142,133, and 125 msec. Previous work has shown that 
this method fails to produce ventricular dysrhythmias in 
sham-operated animals without previous myocardial is- 
chemic injury.23 
Two groups of postinfarction dogs were subjected to 
programmed stimulation testing. Dogs assigned to the 
vehicle control group were subjected to electrophysiologic 
testing and programmed stimulation before and after 
treatment with normal saline solution: four 10 ml intrave- 
nous infusions of 10 minutes duration each, one infusion 
every 8 hours, over a total treatment period of 24 hours. 
After determination of baseline electrophysiologic values 
and pretreatment programmed stimulation testing, dogs 
in the experimental drug treatment group were subjected 
to repeat programmed stimulation testing after d-sotalol 
administration: four 8 mg/kg intravenous infusions, each 
infused in a volume of 10 ml over a period of 10 minutes, 
one infusion every 8 hours, over a total treatment period of 
24 hours. After posttreatment programmed stimulation 
testing and assessment of beta-adrenoceptor blockade by 
isoproterenol infusion, dogs in the vehicle (normal saline 
solution) and d-sotalol treatment groups immediately 
were entered into the protocol for sudden coronary 
death. 
All dogs in this evaluation were assigned randomly to 
their respective treatment groups before pretreatment 
electrophysiologic study. Only dogs which were suscepti- 
ble to the reproducible induction of nonsustained or 
sustained VT by pretreatment programmed stimulation 
were included in this study. VTs were defined as “nonsus- 
tained” if, by using the protocol described previously, five 
or more repetitive ventricular responses were initiated 
reproducibly but terminated spontaneously. Ventricular 
tachyarrhythmias were defined as “sustained” if they 
persisted for at least 30 seconds or, in the event of 
hemodynamic compromise, they required ventricular 
burst pacing for their termination. If VT degenerated into 
ventricular fibrillation, the animal was excluded from the 
study to avoid the potentially confounding influence of 
occasionally prolonged resuscitative efforts on the out- 
come of the second phase of the investigation. If nonsus- 
tained VT could be initiated reproducibly, more aggres- 
sive attempts to induce sustained tachycardia were not 
made. Animals responding with less than five nonstimu- 
lated complexes during the entire protocol were designat- 
ed as noninducible. Dogs were entered randomly into the 
programmed stimulation protocol until an n of 8 was 
attained in the sudden coronary death protocol (below). 
Due to technical failures associated with this latter proto- 
col, an n of >8 was realized for each of the treatment 
groups for the programmed stimulation protocol. 
In vivo assessment of beta-adrenergic receptor 
blockade. The sinus heart rate and systemic diastolic 
blood pressure responses to the rapid intravenous infusion 
of 0.2 pg/kg isoproterenol were determined immediately 
before and after the appropriate 24-hour treatment period 
in vehicle and drug treatment groups. The dose of isopro- 
terenol had been determined to approximate the ED50 
dose for the aforementioned responses in untreated pos- 
tinfarction dogs. In this evaluation, the postinfarction 
dogs were challenged with one infusion of isoproterenol in 
order to minimize the induction of malignant ventricular 
arrhythmias by repeated catecholamine administration 
during this phase of the evaluation. 
Conscious canine model of sudden coronary death- 
ventricular fibrillation in response to ischemia at a site 
remote from previous myocardial infarction. After com- 
pletion of final posttreatment programmed ventricular 
stimulation testing, an anodal direct current of 150 PA was 
applied to the intimal surface of the left circumflex 
coronary artery via the previously inserted silver wire 
electrode. The lead II ECG was recorded directly onto a 
Grass polygraph or was recorded at preset intervals by a 
programmable cardiocassette recorder. 
Upon completion of the experiment at 24 hours of 
electrical stimulation or upon development of ventricular 
fibrillation, the heart was excised and thrombus mass 
within the left circumflex coronary artery was determined 
after removal by careful dissection. The heart was cut into 
1 cm thick transverse sections which were placed in 0.5% 
triphenyltetrazolium chloride in O.OlM phosphate buffer 
(pH 7.4). Infarct size was quantitated gravimetrically with 
the aid of the differential histochemical staining tech- 
nique. 
Drug administration. The resolved dextrorotatory iso- 
mer of sotalol (Mead Johnson Laboratories) was provided 
as a monohydrochloride salt. Indicated dosages reflect 
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Fig. 2. Effects of administration of saline solution vehicle, 10 ml intravenously every 8 hours four times 
(left, n = ll), or d-sotalol, 8 mg/kg intravenously every 8 hours four times (right, n = 9), upon the 
responses of postinfarction dogs to programmed ventricular stimulation. In these figures, each symbol 
represents one animal, with the nature of the response of each animal to programmed stimulation listed on 
the Y-axis. For each treatment group, the response of the animals to programmed stimulation both before 
(PRE) and after (POST) the appropriate treatment is depicted. Before treatment in both groups, the 
introduction of one to three ventricular extrastimuli (see Methods for stimulation protocol) elicited 
nonsustained or sustained ventricular tachycardia (VT) in each of the postinfarction dogs. Right, 
Administration of d-sotalol (POST) suppressed the induction of VT in six of nine dogs tested in this study 
(i.e., six dogs were rendered noninducible). Left, In the vehicle control group (POST), 10 of 11 dogs 
remained inducible after 24-hour administration of saline solution. 
Table I. Programmed ventricular stimulation 
Parameter 
Vehicle d-Sotalol 
(n = 11) (n = 9) 
Pretreatment VT cycle length (msec) 173 f 9 154 f 19 
Posttreatment VT cycle length (msec) 190 + 15* 253 k 35t 
Incidence of prolongation (~20~; ) of 3/10* mt 
VT cycle length with treatment 
Incidence of noninducibility with l/11 6191 
treatment 
Incidence of spontaneous ventricular 
ectopy with treatment 
O/l 1 4191 
Underlying anterior infarct size (CC, of 25.4 k 3.6 22.5 + 4.1 
left ventricle) 
‘N = 10, with one dog noninducible. 
tN = 3, with six dogs noninducible; the appropriate pretreatment cycle 
lengths for this subset of three dogs are 211 i 43 msec. 
tp < 0.05 vs vehicle-treated group. 
dosages of the base compound. Normal (0.970 aqueous) 
saline solution was used as a vehicle throughout. 
Statistical analysis. For all evaluations, data are 
expressed as mean 2 SEM. Pre- and posttreatment val- 
ues within a given treatment group were compared by 
paired Student’s t test. Differences between treatment 
groups were analyzed by unpaired Student’s t test or by 
Fisher’s exact test when appropriate. For all comparisons, 
a p value of less than 0.05 was the criterion for statistical 
significance. 
RESULTS 
Twenty-eight conscious dogs were subjected to 
programmed ventricular stimulation 3 to 5 days 
after anterior myocardial infarction. Six dogs were 
found to be noninducible before treatment and were 
entered into an alternate study. Two dogs responded 
to programmed stimulation with ventricular fibrilla- 
tion and were not resuscitated. The remaining 20 
dogs, randomly preassigned to the vehicle (n = 11, 
10 ml of 0.9% aqueous saline intravenously every 8 
hours, four administrations over 24 hours) or d- 
sotalol (n = 9, 8 mg/kg intravenously every 8 hours, 
four doses over 24 hours) treatment groups, 
responded to pretreatment programmed stimulation 
with reproducible nonsustained or sustained VTs. 
The antiarrhythmic and electrophysiologic re- 
sponses of the vehicle- and d-sotalol-treated ani- 
mals to their respective interventions are presented 
below. 
Programmed electrical stimulation. The responses of 
postinfarction dogs to programmed stimulation, 
before and after d-sotalol or vehicle treatment, are 
summarized graphically in Fig. 2 and are character- 
ized in Table I. Neither the cycle lengths of the 
induced pretreatment tachycardias nor the sizes of 
the underlying anterior infarcts varied significantly 
between the two treatment group (Table I). 
The administration of d-sotalol in this protocol 
suppressed the induction of ventricular tachyarr- 
hythmia by programmed stimulation in six of nine 
dogs tested and furthermore increased the cycle 
length (reduced the rate) of the induced tachyar- 
rhythmia in two of the three remaining animals (Fig. 
WAume 109 
Number 5. Part 1 Antifibrillatory effects of d-sotalol 953 
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Fig. 3. Programmed electrical stimulation on a conscious postinfarction dog before (PRETREATMENT, 
upper panel) and after (POST d-SOTALOL, lower panels) administration of 8 mg/kg intravenous 
d-sotalol every 8 hours, four doses over 24 hours. Before the drug, introduction of three ventricular 
extrastimuli (S,S,S,) at critical coupling intervals elicits a sustained ventricular tachycardia (VT) with a 
cycle length (VT-CL) of 115 msec. After d-sotalol administration, the introduction of ventricular 
extrastimuli in the same range of coupling intervals elicits only one or two ventricular complexes in 
response, thus rendering the animal noninducible. Numbers in parentheses indicate the S1-S2, S2-S3, and 
S,-S, coupling intervals in msec. Depicted ECG is lead II. 
Table II. ECG and electrophysiologic responses 
Parameter 
Heart rate (bpm) 
Mean arterial pressure (mm Hg) 
PR interval (msec) 
QRS interval (msec) 
QTC interval (msec) (sec)-‘12 
Paced QT interval (msec) 
Ventricular excitation threshold (V) 
Ventricular refractory period (msec) 
Ventricular activation time-normal zone 
(msec) 
Ventricular activation time-infarct zone 
(msec) 
Vehicle d-Sotalol 
Before After Before After 
118 t 5 106 + 8 123 ?z 7 99 2 4* 
78 + 4 80 + 4 71 + 3 II + 2 
119 * 4 121 + 4 115 * 4 124 YI 4 
59 k 1 59 -+ 1 60 k 1 58 z!z 1 
301 t 11 295 * 10 304 c 12 318 + 8* 
203 f  6 208 * 4 199 + 7 225 + 6* 
2.0 i 0.2 1.9 F 0.2 2.1 +_ 0.2 2.6 t 0.4 
155 f  5 150 2 5 148 + 4 164 t 5* 
18.8 f  1.8 18.8 + 2.3 16.6 * 1.9 17.1 f  1.7 
26.3 + 3.4 27.3 2 2.7 22.2 zk 1.3 22.9 + 1.4 
*p < 0.05 after vs before. 
2, Table I). Dextrorotatory sotalol appeared to be 
most effective in suppressing the induction of 
tachyarrhythmias in those dogs characterized by 
pretreatment tachycardias of short cycle lengths 
(pretreatment tachycardia cycle length of d-sotalol 
“protected” dogs vs “unprotected” dogs: 125 +- 7 
msec vs 211 f 42 msec) and/or requiring closely 
coupled extrastimuli for arrhythmia induction. In 
contrast, 24-hour vehicle treatment had a minimal 
effect upon the induction of ventricular tachyar- 
rhythmias by programmed ventricular stimulation 
(Fig. 2, Table I). The overall rate of complete 
effectiveness (suppression of tachycardia induction) 
was significantly greater with d-sotalol (six of nine, 
67 % ) than with saline solution vehicle (l/11, 9% ; 
p < 0.05). 
The experiment depicted in Fig. 3 illustrates the 
suppression of electrically induced VT by d-sotalol. 
In this example, before drug administration (upper) 
the introduction of three ventricular extrastimuli at 
critical coupling intervals elicits a sustained ventric- 
ular tachyarrhythmia with a cycle length of 115 
msec. After 24-hour d-sotalol treatment (lower), the 
introduction of three extrastimuli in the same range 
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DIASTOLIC BLOOD PRESSURE 
RESPONSE 
Fig. 4. In vivo assessment of beta-adrenergic receptor 
blockade: Sinus heart rate (upper) and systemic diastolic 
blood pressure (lower) responses of d-sot,alol (right)- and 
vehicle (left&treated postinfarction dogs to rapid infusion 
of 0.2 pg/kg isoproterenol were determined immediately 
before (PRE) and after (POST) their respective 24-hour 
treatment periods. d-Sotalol treatment (right) slightly but 
significantly reduced the positive chronotropic response 
to isoproterenol, while the diastolic pressure response in 
d-sotalol-treated dogs was unaltered. Vehicle treatment 
(left) did not significantly alter heart rate or blood 
pressure response to isoproterenol. n = Y-I 1; *p, < 0.05 
POST vs PRE. 
Table 111. Conscious canine model of sudden death 
Increase in heart rate upon S’I +4j + 5 +x 4 ItI 
segment change ( “, of preischemic 
rate) 
lncidenre of “sudden” * ventricular ‘; ;x 1 /X-l- 
tibrillation upon ischcmia 
24-Hour survival rate I )/X she 
Infarct size ( “(, of left ventricle) 
Left anterior descending “1.7 ? 3.1 18.9 5 2.9 
Left circumflex 33.3 i 3.9 
In = 71 
Thrombus mass (mg) 5.:1 ? I.:, 11.1 f 2.6 
‘Incidence of ventricular fibrillation within fi0 minutes of ischemia. 
tp < 0.05 YS vehicle-treated group. 
of coupling intervals elicits only one or two ventric- 
ular complexes in response, thereby rendering the 
animal noninducible. 
Electrophysiologic responses. Table II summarizes 
0 d-SOTALOL 03 mg/kg x 4,n=8) 
l VEHICLE (n=8) 
4 a 12 16 20 24 
HOURS AFTER ISCHEMIA 
Fig. 5. Survival rates of d-sotalol- and saline-pretreated 
dogs after development of posterolateral ischemia follow- 
ing left circumflex intimal injury. At 24 hours after the 
development of posterolateral ischemia in the presence of 
an anterior myocardial infarct, d-sotalol (8 mg/kg intrave- 
nously every 8 hours, four doses over 24 hours) significant- 
ly increased (p < 0.05) survival compared to saline-treated 
vehicle control dogs. 
the electrophysiologic, ECG, heart rate, and system- 
ic blood pressure responses of postinfarction dogs to 
24-hour vehicle or d-sotalol treatment. d-Sotalol 
treatment significantly increased the ventricular 
effective refractory period but did not alter ventric- 
ular activation (conduction) times or excitation 
threshold. The administration of d-sotalol also pro- 
longed both the QT, interval and the paced QT 
interval while the PR and QRS intervals were 
unaltered. Both the d-sotalol and vehicle posttreat- 
ment heart rates were less than their respective 
pretreatment values, with the d-sotalol posttreat- 
ment value significantly less than the pretreatment 
value. The magnitudes of the reduction in heart rate 
for the two treatment groups, however, did not differ 
significantly. Vehicle administration did not signifi- 
cantly alter electrophysiologic parameters or ECG 
intervals (Table II). Neither d-sotalol nor vehicle 
treatment significantly altered mean arterial pres- 
sure in the postinfarction dogs (Table II). 
Beta-adrenergic receptor blockade. Fig. 4 summa- 
rizes the heart rate and systemic diastolic blood 
pressure responses of d-sotalol- and vehicle-treated 
dogs, immediately before and after their respective 
24-hour treatments, to the rapid intravenous infu- 
sion of 0.2 pg/kg isoproterenol. d-Sotalol administra- 
tion slightly but significantly reduced the positive 
chronotropic response of postinfarction dogs to the 
catecholamine, while the diastolic blood pressure- 
lowering response was unaltered. Vehicle adminis- 
tration altered neither the heart rate nor blood 
pressure response to isoproterenol (Fig. 4). Neither 
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Fig. 6. Ventricular fibrillation in a vehicle-pretreated conscious dog in response to the dev&pment of 
posterolateral ischemia in the presence of an anterior myocardial infarct. An anodal current of 150 PA wds 
applied to the intimal surface of the left circumflex (LCX) coronary artery at time 0. ECG alterations 
reflecting acute ischemia (increasing R wave amplitude, reflex tachycardia) were obserxisd at, 152 minutes 
of current, followed rapidly by the development of ventricular ectopy, tachycardia, and c~ezt.ric&u 
fibrillation at 153 minutes of current. Depicted ECG is lead II. 
d-sotalol nor vehicle pretreatment blunted the sym- 
pathetically mediated reflex tachycardic response to 
the development of acute posterolateral ischemia in 
the postinfarction dogs (Table III). 
Spontaneous ventricular ectopic activity. Transient 
episodes of spontaneous ventricular ectopic activity 
were observed in four of nine d-sotalol-treated dogs 
during or immediately after drug infusion. These 
episodes of ventricular ectopy were suppressed 
readily by atria1 pacing at a rate slightly exceeding 
that of the sinoatrial rate. The occurrence of ventric- 
ular ectopy did not appear to correlate with the 
degree of QT prolongation in the d-sotalol-treated 
animals, as the absolute increase in paced QT 
interval in the ectopic animals (+20 -t 6 msec) was 
actually slightly (but not significantly) less than the 
increase observed in nonectopic dogs (+35 f 8 
msec). Episodes of spontaneous ventricular ectopy 
were not observed during or after vehicle infusion. 
Conscious canine model of sudden coronary death. 
Immediately after the posttreatment assessment of 
the abilities of d-sotalol or vehicle to influence the 
induction of VT by programmed electrical stimula- 
tion, an anodal current of 150 PA was applied to the 
intimal surface of the left circumflex coronary artery 
in each of eight dogs in the two treatment groups. 
The responses of the two treatment groups to left 
circumflex intimal stimulation are summarized in 
Table III. The times to the development of ECG 
evidence of posterolateral ischemia in the two 
groups were comparable, and the reflex tachycardic 
responses to posterolateral ischemia as well as the 
masses of the underlying auterlo; infarcts ilid not 
differ significantly between the two treatment 
groups (Table III). 
The responses of d-sotalol- aud vehicle-pre- 
treated dogs to posterolateral ischemia in the pres- 
ence of a previous anterior infarction are compared 
graphically in the survival curves depicted in Fig. 5. 
Pretreatment with vehicle afforded minimal protec- 
tion against the development of sudden ventricular 
fibrillation in this evaluation. In the vehicle-treated 
group, seven of eight dogs dateloped ventricular 
fibrillation within 13 ~fr 6 mint&es of the EC@ man- 
ifestation of posterolateral iscbtmia as assessed by 
alterations in the lead II ECG recording. The one 
remaining animal died of ventricular fibrilltition 108 
minutes after the onset of lqional ischemia. An 
example of sudden ventricular fibrillation in t,he 
vehicle treatment group is showi] in Fig. 6. 
Pretreatment with d-sotalol (8 mg/kg irkrave- 
nously every 8 hours, four doses over 24 hours) 
provided significant protection against the develop- 
ment of ventricular fibrillation occurring in response 
to posterolateral ischemia in postinfarction dogs 
(Fig. 5, Table III). In the d-sotalol-treated group, 
only one of eight dogs died of ventricular fibrillation 
within the first 60 minutes of ischemia and five dogs 
survived the entire 24-hour protocol. Late s.rrhyth- 
mic deaths and 24-hour survivals in this treatment 
group displayed histochemical evidence of myocar- 
dial infarction in the left circumfiex dist,ribution, a 
rare finding in vehicle-treated animals because of 
the rapidity of the development, of ‘Tentricular fibril 
966 Lynch et al. 
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Fig. 7. Cumulative survival rates of multiple-dose d- 
sotalol (four 8 mg/kg intravenous doses over 24 hours), 
single-dose d-sotalol (one 8 mg/kg intravenous dose),22 and 
saline vehicle-pretreated dogs after the development of 
posterolateral ischemia in the presence of an anterior 
myocardial infarction. These data indicate an enhanced 
protection with multiple-dose vs single-dose d-sotalol 
pretreatment in this sudden death model. 
lation in unprotected animals. d-Sotalol-pretreated 
survivors in this evaluation, therefore, possessed 
both anterior and posterolateral infarcts cumula- 
tively comprising approximately 40% of the total 
left ventricular mass (Table III) and were fully 
ectopic at 24 hours after the onset of posterolateral 
ischemia. Cumulative survival rates of multiple-dose 
d-sotalol (four 8 mg/kg intravenous doses over 24 
hours), single-dose d-sotalol (one 8 mg/kg intrave- 
nous dose)22, and saline solution, vehicle-pretreated 
postinfarction dogs in this sudden death model are 
compiled and presented in Fig. 7. These cumulative 
survival data indicate an enhanced protection with 
multiple-dose vs single-dose d-sotalol pretreatment 
in this conscious canine model of sudden coronary 
death. 
DISCUSSION 
Conscious canine model of sudden coronary death. 
The conscious postinfarction canine model used in 
this study has been developed in order to assess the 
potential efficacy of pharmacologic interventions in 
protecting against sudden coronary death.23 As uti- 
lized by this laboratory, the postinfarction canine 
model is susceptible to the reproducible induction of 
presumably reentrant ventricular tachyarrhythmias 
by programmed ventricular stimulation, and sud- 
denly and reliably responds to an acute ischemic 
event at a site distant from an area of previous 
myocardial infarction with the development of ven- 
tricular fibrillation.23s24 Clinically, over one half of all 
sudden deaths occur in subjects with previous myo- 
cardial infarction.25-28 Furthermore, ventricular 
tachyarrhythmias may be induced by programmed 
ventricular stimulation in the majority of patients 
resuscitated from sudden death,25s 27-2g thereby indi- 
cating the presence of an electrically vulnerable 
myocardial substrate which may entertain a poten- 
tially lethal arrhythmia, and providing a potential 
means by which pharmacologic therapy may be 
directed for the prevention of lethal arrhythmias 
and sudden death. Finally, recent evidence suggests 
that transient acute ischemia may constitute an 
important triggering event for the development of 
lethal arrhythmias and sudden death in postinfarc- 
tion patients.“Ol”’ The postinfarction dog model used 
in the present evaluation incorporates many of the 
etiologic features of sudden death and therefore may 
constitute a relevant model in which to assess 
pharmacologic agents for the prevention of sudden 
coronary death. 
Antiarrhythmic and antifibrillatory actions of dextro- 
rotatory sotaioi. In the present study, the administra- 
tion of d-sotalol in a multiple-dose regimen (four 8 
mg/kg intravenous doses over a 24-hour period) 
prevented the induction of VT by programmed 
ventricular stimulation in six of nine (67%) postin- 
farction dogs tested. This degree of efficacy against 
programmed stimulation-induced tachycardias is 
comparable to that reported for the single-dose 
acute administration of 8 mg/kg intravenous d- 
sotalol(54% )” and for the single-dose acute admin- 
istration of racemic d,l-sotalol, 4.5 mg/kg intrave- 
nously (58% )I8 or 8.0 mg/kg intravenously (56% ),lg 
in similar postinfarction dog models. The selective 
increase in ventricular myocardial refractoriness in 
conjunction with the prolongation of paced QT and 
QT, intervals (general indices of action potential 
duration) suggest that the direct class III electro- 
physiologic actions of d-sotalol (i.e., a selective 
prolongation of action potential duration resulting 
in increased cellular refractoriness) may contribute 
to the antiarrhythmic actions of the isomer in the 
postinfarction dog model. In contrast, the unimpres- 
sive degree of beta-adrenergic receptor blockade 
produced by d-sotalol in this preparation, as well as 
the previously demonstrated lack of efficacy of the 
beta-adrenoceptor blockers metoproloP and nado- 
loP2 against the induction of VT by programmed 
electrical stimulation in postinfarction dogs, argued 
against beta-adrenergic receptor blockade playing a 
role in the suppression of VT induction during 
programmed stimulation by the dextrorotatory iso- 
mer of sotalol. 
Administered in a multiple-dose pretreatment 
regimen (four 8 mg/kg intravenous doses over 24 
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hours), dextrorotatory sotalol provided significant 
protection against the development of ventricular 
fibrillation occurring in response to ischemia at a 
site distant from a previous infarction. The degree of 
protection afforded by this multiple-dose pretreat- 
ment was markedly greater than that afforded by a 
single-dose, acute pretreatment with 8 mg/kg intra- 
venous d-sotalol in a previous investigation.22 The 
enhanced efficacy of this multiple-dose regimen is 
presumably the result of optimization of drug plas- 
ma concentrations and/or cardiac tissue levels in the 
postinfarction dogs. Previous studies in this labora- 
tory have identified the class III antiarrhythmic 
agents bretylium33 and amiodarone,34 the class III 
antiarrhythmic and beta-adrenoceptor-blocking 
agent d,l-sotalol,ls and the beta-adrenergic receptor 
antagonist d,l-nadolol,32 the latter apparently devoid 
of direct electrophysiologic actions, as providing 
significant protection against the development of 
ventricular fibrillation in response to ischemia at a 
site distant from a previous infarction. It may not be 
presumed, therefore, that the slight degree of beta- 
adrenoceptor blockade produced by d-sotalol in this 
preparation might not contribute to the antifibrilla- 
tory action of the isomer in the sudden death 
protocol. The slight degree of beta-adrenergic recep- 
tor blockade exhibited by d-sotalol in this regimen, 
however, does suggest that this agent may be tolera- 
ble in the setting of ventricular dysfunction. 
During the present multiple-dose regimen, four of 
nine postinfarction dogs receiving dextrorotatory 
sotalol developed ventricular ectopic activity during 
or immediately after drug infusion. The develop- 
ment of ventricular premature complexes, with a 
comparable rate of occurrence and similar in charac- 
teristics of overdrive suppression, has been noted 
previously with the acute single-dose administration 
of the dextrorotatory but not the levorotatory iso- 
mer of sotalo1.22 In the present study, with small 
sample sizes, the development of transient ventricu- 
lar ectopy upon d-sotalol administration did not 
correlate with the degree of QT interval prolonga- 
tion. Further study will be required to determine the 
underlying mechanism of the d-sotalol-induced ven- 
tricular ectopy and to ascertain to what extent, this 
adverse effect may limit the use of the agent. 
Conclusions. In conscious dogs in the subacute 
phase of myocardial infarction, the dextrorotatory 
isomer of sotalol, administered in a multiple-dose, 
24-hour treatment regimen, significantly suppressed 
the induction of VT by programmed ventricular 
stimulation and significantly protected against the 
development of ventricular fibrillation in response 
to ischemia at a site distant from a previous infarct. 
Antifibrillatory effects of d-sotalol 957 
Alterations in ventricular refractoriness, QT,, and 
paced QT intervals suggest that direct class III 
electrophysiologic actions (prolonged action poten- 
tial duration, resulting in increased cellular refracto- 
riness) might underlie, in part, the antiarrhythmic/ 
antifibrillatory actions of d-sotalol in this prepara- 
tion. The degree of beta-adrenergic receptor block- 
ade produced by d-sotalol in this regimen was slight 
and unimpressive. These findings suggest the poten- 
tial utility of d-sotalol in the prevention of VT and 
ventricular fibrillation in the setting of myocardial 
infarction. 
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